Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 25, 2020 - Issue 2
Submit an article Journal homepage
966
Views
8
CrossRef citations to date
0
Altmetric
Review

Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials

Andrea Barpa NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, Italy;b Dept. Biomedical Sciences of Health, University of Milan, Milan, ItalyView further author information
,
Francesca Gerardia NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, ItalyView further author information
,
Andrea Lizioa NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-8875-9665View further author information
ORCID Icon,
Valeria Ada Sansonea NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, Italy;b Dept. Biomedical Sciences of Health, University of Milan, Milan, ItalyView further author information
&
Christian Lunettaa NEuroMuscular Omnicentre, Fondazione Serena Onlus, Milan, ItalyCorrespondence[email protected]
View further author information
Pages 145-164 | Received 06 Mar 2020, Accepted 11 May 2020, Published online: 27 May 2020

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Eitan Raveh, Assaf Ben-Shimon, Vova Anisimov, Rivka Kreitman, Edmund Ben-Ami, Elisheva Nechushtan, Nurit Birman & Vivian E Drory. (2023) Correlation between oculometric measures and clinical assessment in ALS patients participating in a phase IIb clinical drug trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24:5-6, pages 495-501.
Read now

Articles from other publishers (7)

Xiaoting Zheng, Shichan Wang, Jingxuan Huang, Junyu Lin, Tianmi Yang, Yi Xiao, Qirui Jiang, Rui Huang, Chunyu Li & Huifang Shang. (2023) Physical activity as risk factor in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Journal of Neurology 270:5, pages 2438-2450.
Crossref
Kim A. Staats, David R. Borchelt, Malú Gámez Tansey & James Wymer. (2022) Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Molecular Neurodegeneration 17:1.
Crossref
Peter Bloomingdale, Tatiana Karelina, Vidya Ramakrishnan, Suruchi Bakshi, Florence Véronneau‐Veilleux, Matthew Moye, Kazutaka Sekiguchi, Guy Meno‐Tetang, Aparna Mohan, R. Maithreye, Veena A. Thomas, Frank Gibbons, Antonio Cabal, Jean‐Marie Bouteiller & Hugo Geerts. (2022) Hallmarks of neurodegenerative disease: A systems pharmacology perspective. CPT: Pharmacometrics & Systems Pharmacology 11:11, pages 1399-1429.
Crossref
Ann Logan, Antonio Belli, Valentina Di Pietro, Barbara Tavazzi, Giacomo Lazzarino, Renata Mangione, Giuseppe Lazzarino, Inés Morano, Omar Qureshi, Lars Bruce, Nicholas M. Barnes & Zsuzsanna Nagy. (2022) The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis. Frontiers in Pharmacology 13.
Crossref
Belgin Sever, Halilibrahim Ciftci, Hasan DeMirci, Hilal Sever, Firdevs Ocak, Burak Yulug, Hiroshi Tateishi, Takahisa Tateishi, Masami Otsuka, Mikako Fujita & Ayşe Nazlı Başak. (2022) Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 23:5, pages 2400.
Crossref
Maria Galvez-Llompart, Riccardo Zanni, Ramon Garcia-Domenech & Jorge Galvez. (2022) How Molecular Topology Can Help in Amyotrophic Lateral Sclerosis (ALS) Drug Development: A Revolutionary Paradigm for a Merciless Disease. Pharmaceuticals 15:1, pages 94.
Crossref
Youcui Wang, Xiaoqin Zhang, Fenghua Chen, Ning Song & Junxia Xie. (2021) In vivo Direct Conversion of Astrocytes to Neurons Maybe a Potential Alternative Strategy for Neurodegenerative Diseases. Frontiers in Aging Neuroscience 13.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.